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Abstract
The transcription factor Miz1 forms repressive DNA-binding complexes with the Myc, Gfi-1 and Bcl-6 oncoproteins. Known
target genes of these complexes encode the cyclin-dependent kinase inhibitors (CKIs) cdkn2b (p15
Ink4), cdkn1a (p21
Cip1),
and cdkn1c (p57
Kip2). Whether Miz1-mediated repression is important for control of cell proliferation in vivo and for tumor
formation is unknown. Here we show that deletion of the Miz1 POZ domain, which is critical for Miz1 function, restrains the
development of skin tumors in a model of chemically-induced, Ras-dependent tumorigenesis. While the stem cell
compartment appears unaffected, interfollicular keratinocytes lacking functional Miz1 exhibit a reduced proliferation and an
accelerated differentiation of the epidermis in response to the tumor promoter 12-O-tetradecanoylphorbol-13-acetate
(TPA). Tumorigenesis, proliferation and normal differentiation are restored in animals lacking cdkn1a, but not in those
lacking cdkn2b. Our data demonstrate that Miz1-mediated attenuation of cell cycle arrest pathways via repression of cdkn1a
has a critical role during tumorigenesis in the skin.
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Introduction
Miz1 (Myc-interacting zinc finger protein 1; Zbtb17) is a zinc
finger transcription factor that forms a complex with the Myc
oncoprotein [1]. In addition to 13 zinc fingers that are clustered in
the central and C-terminal part of the protein, Miz1 bears a POZ
(poxvirus zinc finger protein) domain at the N-terminus [2]. POZ
domains are found in a variety of different transcription factors
and can confer hetero- or homodimerization as well as
tetramerisation [3,4]. The POZ domain of Miz1 forms tetramers
[3] and is required for a stable association of Miz1 with chromatin
[5,6]. In addition, Miz1 lacking the POZ domain can also interact
with other proteins. As a result, the POZ domain is required both
for transcriptional activation and repression by Miz1.
Among the proteins which interact with Miz1 independent of
the POZ domain is Myc, which binds to Miz1 between the zinc
finger domains 12 and 13 [1]. This complex represses the
transcription of genes including cdkn2b (encoding p15
Ink4b), cdkn1a
(encoding p21
Cip1), cdkn1c (encoding p57
Kip2) and mxd4 (encoding
Mad4) [7–10]. In the absence of Myc, Miz1 activates transcription
of a number of genes including Bcl-2 [11], clusterin, several
integrins and other proteins involved in cell adhesion [12], in a
concerted manner with other transcription factors. For example,
Miz1 synergizes with the Smad complex during the TGF-ß
mediated activation of cdkn2b expression [7,8]. Similarly, increased
transcription of cdkn1a depends on Miz1 in response to DNA
damage [9] as well as in models of cellular differentiation [13–15].
Miz1 also forms repressive complexes with the Bcl-6 and Gfi-1
oncoproteins. Both complexes are capable of repressing expression
of cdkn1a, and, in the case of Gfi-1, also of cdkn2b. These
observations suggest that Miz1 functions as a general mediator of
repression in association with several transcription factors
[13,16,17].
The constitutive knockout of Miz1 is lethal at embryonic day
E7.5 [18]. We previously analysed the function of Miz1 in
keratinocytes using a conditional Cre/lox knockout model, in
which the Cre recombinase is targeted via the keratin 14 promoter
to the basal layer of both intra- and interfollicular epidermis [19],
where Miz1 is predominantly expressed [12]. In this model, loxP
sites flank exons 3 and 4, which encode the POZ domain [2], and
deletion of these exons results in expression of a truncated Miz1
protein lacking the POZ domain [20]. Consistent with the
biochemical model described above, keratinocytes lacking the
Miz1 POZ domain show an attenuated expression of Miz1 target
genes in response to TGF-b [20]. Furthermore, animals
homozygous for this deletion exhibit an impaired morphogenesis
of hair follicles with irregular order and extended length of the
follicle, formation of epidermal cysts, delayed catagen during the
hair cycle, loss of zig-zag hairs, as well as the occurrence of
pigment incontinence in older animals [20].
The model described above suggests that Miz1 has a repressive
function in highly proliferative and tumor tissues that express high
levels of Myc, which may not be revealed during normal
development [21]. Recent work by Trumpp and colleagues
demonstrated that endogenous Myc is required for the formation
of skin papillomas. The critical function of endogenous Myc in this
context is to repress expression of cdkn1a, since deletion of c-myc
leads to a loss of tumor formation as well as elevated levels of
p21
Cip1, and co-deletion of cdkn1a fully restores tumor formation
[22]. We now used the conditional Miz1-POZ domain knockout
model to test the role of Miz1 in proliferation, differentiation and
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the Miz1 POZ domain leads to increased differentiation and
reduced proliferation of keratinocytes when skin is challenged by
the tumor promoter agent 12-O-tetradecanoylphorbol-13-acetate
(TPA) as well as strongly decreased papilloma formation. These
alterations are dependent on an altered regulation of cdkn1a
expression. Our findings show that Miz1 is part of a repressor
complex that is critical for restraining p21
Cip1 expression in
response to stimuli that enhance proliferation and promote skin
carcinogenesis.
Results
The number of label retaining cells and the distribution
of stem cell markers are unaffected in Miz1DPOZ mice
The homozygous deletion of the Miz1 POZ domain in
keratinocytes, using a mouse strain that expresses Cre recombinase
under the control of the keratin 14 promoter (hereafter called
Miz1DPOZ mice; corresponding control animals do not express
Cre recombinase; see also Material and Methods), revealed a
complex skin phenotype [20]. To assess whether a defect of the
stem cell compartment, located at the bulge region of the hair
follicle, can account for the observed phenotypes in Miz1DPOZ
mice, we visualized label-retaining cells (LRCs; [23]) by injecting
BrdU on day 10 post partum (P10) and analysed the number and
location of LRCs on P24. No significant morphological difference
in number and location of BrdU positive cells of the bulge region
was detected comparing control and Miz1DPOZ animals (Figure 1
A and B and Figure S1). To test whether enhanced proliferation
has an impact on LRCs, we applied 12-O-tetradecanoylphorbol-
13-acetate (TPA), a known enhancer of keratinocyte proliferation
[24], once per day over five days. Again, no significant difference
in number and location of LRCs of the bulge region was observed
between control and Miz1DPOZ animals (Figure 1 C and D and
Figure S1).
In addition, immunohistochemical stainings for the stem cell
markers K15 (Figure 1 E–H) and CD34 (Figure 1 I–L) [25,26]
revealed no difference in the number and location of labelled cells
between control and Miz1DPOZ animals, irrespective of TPA or
control treatment. Our data indicate that the deletion of the
Miz1DPOZ domain has little effect on the location, number and
proliferation of stem cells in the bulge region of Miz1DPOZ mice.
Alterations of differentiation and proliferation after TPA
treatment are dependent on p21
cip1
Since Miz1, together with Myc, regulates the expression of
genes encoding cyclin dependent kinase inhibitors like cdkn2b
(encoding p15
Ink4b)o rcdkn1a (encoding p21
Cip1) we next asked
whether proliferation, differentiation and apoptosis of interfollic-
ular keratinocytes are affected when a functional Miz1 protein is
missing. The epidermis of control and Miz1DPOZ mice showed no
difference in the expression pattern of the differentiation markers
keratin 1 (Figure 2 A and C), loricrin (Figure 2 E and G) or
filaggrin (Figure S2F and H). Additionally, the number and
location of cells positive for the proliferation marker Ki67 was
unaltered (Figure 2 I, K and M). When mice were treated with
TPA, the thickness of the epidermis increased as expected (Figure
S2A–E), and the expression of the suprabasal differentiation
markers keratin 1 and loricrin, but not filaggrin, was undetectable
in large areas of the epidermis from control animals (Figure 2 B, F
and Figure S2F and G). In contrast, thickening of the epidermis
was slightly but significantly reduced in Miz1DPOZ mice under
TPA treatment (Figure S2E) and all three markers of differenti-
ation remained prominent throughout the epidermis of Miz1D-
POZ mice (Fig. 2 D, H and Figure S2H and I). Furthermore, skin
from Miz1DPOZ mice exhibited keratin 1 staining in lower
suprabasal cell layers, relative to control animals, where keratin 1
expression was mostly restricted to superficial epidermal cell layers
(Figure 2 B and D). We conclude that treatment with TPA delays
the differentiation of keratinocytes in control, but not in
Miz1DPOZ mice.
Consistent with these observations, application of TPA over five
days significantly enhanced the number of Ki67 positive cells in
the epidermis of control animals, but to a much lesser extent in the
epidermis of Miz1DPOZ animals (Figure 2 J, L and M). In
addition, while a considerable number of Ki67 positive cells were
located in suprabasal cell layers in control mice, this was not
observed in Miz1DPOZ mice (Figure 2 J, L), strongly indicating
that the absence of the Miz1 POZ domain prevents cell cycle entry
in response to TPA. Taken together, our findings show that a
decrease of cell proliferation and an earlier onset of increased
differentiation attenuate the effect of TPA in the epidermis of
Miz1DPOZ mice.
To genetically test whether one of the Miz1 regulated cyclin
dependent kinase inhibitors, p15
Ink4b or p21
Cip1, have a role in
restricting proliferation and promoting differentiation of keratino-
cytes in Miz1DPOZ mice, we generated Miz1DPOZ mice that lack
either cdkn2b or cdkn1a. TPA treatment of Miz1DPOZ;cdkn2b
2/2
mice revealed no difference to Miz1DPOZ;cdkn2b
+/+ mice in regard
to differentiation and proliferation of interfollicular keratinocytes,
indicating that p15
Ink4b is not required for restraining proliferation
of Miz1DPOZ keratinocytes (Figure 3E, Figure S3A–D, E). In line
with these findings we didn’t observe changes in p15
ink4b
expression by quantitative RT-PCR (data not shown). In contrast,
keratinocyte proliferation was induced by TPA to the same extent
in Miz1DPOZ;cdkn1a
2/2 animals as in control animals (Figure 3A–
D and F, Figure S3F). In addition, the extended focal ablation of
differentiation markers that was observed in control animals also
occurred in Miz1DPOZ;cdkn1a
2/2 mice, in contrast to Miz1DPOZ
mice (Figure S4). These genetic data show that the impact of Miz1
on keratinocyte proliferation and differentiation depends on
p21
Cip1.
To determine the biochemical basis of these observations, we
analysed p21
cip1 expression by immunoblot analysis of skin from
control and knockout animals with a cdkn1a
+/+ background
(Fig. 3I). Without TPA treatment, expression of p21
cip1 was below
the limit of detection in the skin from control animals but gave a
clear signal in skin from Miz1DPOZ animals. TPA treatment
induced the expression of p21
cip1 in control animals and led to a
further increase in p21
cip1 expression in Miz1DPOZ mice. Under
both conditions p21
cip1 expression was increased in Miz1DPOZ
animals compared to control animals, demonstrating directly that
the Miz1 POZ domain restrains expression of p21
cip1 in vivo.
To rule out the possibility that the increased p21
cip1 expression
was an indirect effect of an altered signal transduction in
Miz1DPOZ animals, we first analysed Myc levels and found by
immunoblot analysis that addition of TPA elevated Myc levels to a
similar extent in control and Miz1DPOZ animals (Figure S5A).
Second, we evaluated the activity of the Ras-Raf-MEK pathway
via detection of phosphorylated ERK (p-ERK) [22]. Immunoblot
analysis revealed a similar phosphorylation of ERK after TPA
treatment in control and Miz1DPOZ animals (Figure S5A). In
addition, p-ERK was detected in the suprabasal cell layers of the
epidermis independent of the genotype (Figure S5B–E). Third,
analysis of expression of p53, a major regulator of cdkn1a,b y
immunoblot and immunohistochemistry revealed no evidence for
a difference between Miz1DPOZ and control animals (Figure S5A,
F and G).
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in keratinocytes, we performed chromatin immunoprecipitation
(ChIP) assays with antibodies directed against Miz1 and Myc,
respectively. Since the isolation of primary keratinocytes takes
several hours under harsh conditions and since it is almost
impossible to obtain sufficient primary keratinocytes for efficient
chromatin isolation, we used the murine keratinocyte cell line
PAM212 [27], which responds to TPA similarly as primary
keratinocytes [28]. Using chromatin isolated from these cells,
ChIP assays revealed that both Miz1 and Myc were bound to the
core promoter region of cdkn1a, but not to a control region located
about 20 Mb downstream of cdkn1a. The binding of Miz1 to the
cdkn1a promoter was not altered under TPA treatment (Figure 3G
and H).
Taken together our data show that (a) cdkn1a is a direct target
gene of Myc and Miz1 in murine keratinocytes,(b) that the POZ
domain of Miz1 is critical for repressing p21
Cip1 expression in vivo
and (c) that elevated levels of p21
Cip1 restrain TPA-stimulated
keratinocyte proliferation in Miz1DPOZ mice.
Reduced skin tumorigenesis in Miz1DPOZ mice
The reduced proliferation response to TPA treatment in the
skin of Miz1DPOZ animals led us to ask whether Miz1 plays a role
in skin tumorigenesis. We applied the well-established two-stage
skin carcinogenesis protocol using 7,2-dimethylbenz(a)anthracene
(DMBA) as tumor initiator and 12-O-tetradecanoylphorbol-13-
acetate (TPA) as tumor promoter [29]. Tumors initially emerged
between weeks 8 and 9 of the TPA treatment both in control (see
Materials and Methods) and in Miz1DPOZ animals, indicating that
the principal time course of tumor development is similar in both
mouse strains (Figure 4A). However, whereas 50% of the control
animals developed tumors between weeks 10 and 11 of TPA
treatment (n=23), it took 15–16 weeks until 50% of the
Miz1DPOZ animals exhibited tumors (Figure 4A; n=26;
p,0.001). To exclude that the tumors observed in Miz1DPOZ
mice developed from keratinocytes that have escaped Cre
recombination, we isolated DNA from tumor samples and
genotyped them by PCR. In all 45 tumors tested we could
confirm efficient Cre-mediated recombination (Figure S6I). Since
skin papillomas in this animal model are usually monoclonal
[29,30], a recombinant band indicates that the tumor has
descended from a recombined keratinocyte. The non-recombined
bands almost certainly come from cells of epidermal (melanocytes,
dendritic cells) and/or dermal (fibroblasts, dendritic cells and
many others) origin, in which the Cre recombinase is not active.
This indicates that the tumors have not grown from escaper
clones, but from cells lacking the Miz1 POZ domain. The gross
morphology of tumors of comparable size from control and
Miz1DPOZ animals was identical. No difference in the pattern of
outfoldings was observed. In both genotypes, the thicknesses of the
epidermis and of the cornified layer, and the amount of
keratohyalin granules were increased compared to the interfollic-
ular epidermis. Finally, no spread of epidermal cells into the
dermal compartment occurred (Figure S6A–H).
The decreased tumorigenesis in Miz1DPOZ mice was further
reflected by a reduced tumor burden per mouse, since the number
of tumors was significantly lower in Miz1DPOZ compared to
control animals (Miz1DPOZ: n=3.3864.30 tumors per mouse
measured in 26 mice; control: n=8.3565.16 tumors per mouse
measured in 23 mice; p,0.001; Figure 4B). Furthermore, tumors
at the end of TPA treatment were significantly smaller in
Miz1DPOZ mice than in control mice (1.9461.64 mm vs
2.9361.73 mm; Figure 4E and H). To exclude that the reduced
tumor size is caused by increased apoptosis, we performed a
Figure 1. The skin stem cell compartment is unaltered in Miz1DPOZ mice. Animals, which were labelled on day P10 with BrdU, showed label-
retaining cells two weeks later, predominantly located in the bulge region of the hair follicle. No difference was observed between control (Ctr) and
Miz1DPOZ mice, neither without nor with TPA treatment (A–D). Skin stem cell markers Keratin 15 (K15; E–H) and CD34 (I–L) did not reveal differences
between the different genotypes or treatments. Number of animals analysed: n=3 for F–J and L; n=4 for B, C and E; n=5 for D and K; n=6 for A. Bar:
50 mm.
doi:10.1371/journal.pone.0034885.g001
Miz1 and Tumorigenesis in Skin
PLoS ONE | www.plosone.org 3 April 2012 | Volume 7 | Issue 4 | e34885Figure 2. Epidermal differentiation and proliferation is altered upon TPA treatment. Immunohistochemical staining revealed no
difference in the expression of the differentiation markers keratin 1 or loricrin (A, C and E, G) in the epidermis of untreated control (Ctr)o rMiz1DPOZ
mice. When Ctr animals were treated with TPA, focal areas were observed lacking these differentiation markers (B, F). In contrast, such foci did not
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tumors of both genotypes and were almost absent in the
interfollicular epidermis (Figure S7A), indicating that the tumor
size in Miz1DPOZ mice is not affected by increased programmed
cell death. Finally, when TPA treatment was finished after 20
weeks and mice were subsequently observed for further 17 weeks,
tumor diameter increased about threefold in control animals but
remained constant in Miz1DPOZ mice (Figure S7B and C). We
conclude that tumor development and growth is strongly reduced
in Miz1DPOZ mice.
Strikingly, immunohistochemistry of papillomas revealed low
levels of p21
cip1 in keratinocytes from 19 out of 21 tumors from
control animals, but high p21
cip1 levels in keratinocytes from 14
out of 15 tumors of Miz1DPOZ mice (Figure 4F and G; Figure
S8A). Additionally, increase of p21
cip1 in papillomas from
Miz1DPOZ mice was observed by immunoblot analysis (Figure
S8B). To test the impact of p21
cip1 genetically, we monitored
tumor development in a cohort of Miz1DPOZ;cdkn1a
2/2 mice. In
these experiments, we noted that the tumor burden per mouse in
cdkn1a
2/2 control animals (Figure 4D) was lower than in cdkn1a
+/+
control animals (Figure 4B), most likely due to subtle differences in
the overall genetic background of the animals used in the two
experiments (see Materials and Methods) or possibly to a general
lower tumor incidence in p21
cip1 deficient animals [31,32].
Importantly, Miz1DPOZ;cdkn1a
2/2 animals developed tumors
with a time course that was indistinguishable from control
cdkn1a
2/2 animals (Figure 4C; p=0.6933). Furthermore, the
difference of tumor burden between cdkn1a
2/2;Miz1DPOZ and
their corresponding control mice was smaller (5.0467.03 vs
6.2765.74 tumors per mouse, measured in 22 control and 26
cdkn1a
2/2;Miz1DPOZ mice; p=0.5139) than in an cdkn1a
+/+
background (8.35 vs 3.38 tumors per mouse, see above). Finally,
there was no difference in the tumor size between control and
Miz1DPOZ animals in a cdkn1a
2/2 background (Figure 4I), in
contrast to control and Miz1DPOZ animals with a cdkn1a
+/+
background (Figure 4H). Taken together, we conclude that the
reduced tumorigenicity observed in Miz1DPOZ mice depends on
the upregulation of p21
Cip1 expression.
Discussion
One well characterized function of Miz1 is the regulation of the
cyclin dependent kinase inhibitor genes cdkn2b (encoding p15
Ink4b),
cdkn1a (encoding p21
Cip1) and cdkn1c (encoding p57
Kip2) [33],
although a number of other genes are now known to be expressed
in a Miz1-dependent manner [6,11,12]. The current model
proposes that Miz1, complexed with nucleophosmin, binds to the
core promoter of its target genes to enhance gene expression.
Transactivation is blocked when the Myc/Max complex binds to
Miz1, thereby releasing nucleophosmin [34,35]. In this model,
Miz1 has a dual role in expression of its target genes. In the
absence of Myc, Miz1 contributes to target gene activation.
However, Miz1 also serves to recruit Myc leading to the formation
of a repressive complex. This suggests that abrogation of Miz1
function will enhance target gene expression in conditions of high
Myc expression. The allele of Miz1 used here lacks the POZ
domain, which is necessary both for the transactivating properties
of Miz1 [1,9] and for its stable association with chromatin [6,21].
We observed fewer and smaller tumors in Miz1DPOZ animals.
A detailed analysis revealed that a reduced proliferation of
keratinocytes in response to the tumor promoter, TPA, can
account for the reduction of tumor growth in these animals, while
changes in the stem cell compartment could not be uncovered.
Interestingly, proliferation was completely restored in a cdkn1a null
background, strongly suggesting that the increase in p21
Cip1
expression that is observed in Miz1DPOZ mice is responsible for
the observed phenotype. This notion is further supported 1) by an
immunoblot analysis revealing elevated p21
cip1 levels in the skin
from Miz1DPOZ mice compared to their wildtype counterparts
(Fig. 3I), 2) by immunohistochemical data showing that p21
Cip1 is
consistently expressed in tumors of Miz1DPOZ mice, but is hardly
detectable in control tumors (Fig. 4F, G) and 3) by the genetic
experiment exhibiting a rescue of the reduced proliferation
reflected by Ki67 positive cells (Figure 3A–D and F), a rescue of
the tumor development (Figure 4C) and partial rescue of the
tumor burden (Figure 4D) in Miz1DPOZ mice on a cdkn1a null
background. In contrast, Miz1DPOZ mice with a cdkn2b null
background exhibited only a small and statistically insignificant
increase in Ki67 positive cells (Figure 3E; Figure S3A–E),
suggesting that upregulation of p15
Ink4b is not involved in
restraining proliferation of Miz1DPOZ keratinocytes in response
to TPA treatment.
While our data show that Miz1 has a critical role in repressing
cdkn1a expression during skin carcinogenesis, they do not directly
address the mechanism by which Miz1 acts in this system. For
example, Miz1 has been suggested to associate with p53 [36].
While deletion of the POZ domain does not affect levels of p53
(Figure S5A), it is possible that it enhances p53 function in more
subtle ways, leading to enhanced p21
cip1 expression. Furthermore,
we do not know which of the several oncoproteins that can repress
transcription via Miz1 (see Introduction) are functional during skin
carcinogenesis. However, our data can account for the results
obtained using tamoxifen inducible c-myc
2/2 mice [22]. In these
mice, DMBA/TPA treatment led to elevated expression of p21
Cip1
and skin tumors could only be induced in the absence of p21
Cip1,
demonstrating that endogenous Myc has a critical function in
repressing cdkn1a during skin tumor development. It should be
noted, that a related model in which c-myc is deleted during
development by a constitutively active Cre recombinase expressed
under the keratin 5 promoter shows more severe phenotypes,
suggesting that Myc has functions in addition to repressing p21
cip1
during skin development [37].
Our data extend observations on Myc-induced lymphomagen-
esis in mice expressing a mutant allele of Myc that is selectively
deficient in binding to Miz1 (MycV349D). Mice expressing this
mutant display a reduced tumorigenesis, at least in part because
binding of Myc to Miz1 is required to restrain expression of
p15
Ink4b and of p57
kip2 in the lymphomas [38]. Importantly,
lymphomas arising in these mice showed an accumulation of
senescent cells, suggesting that binding of Myc to Miz1 may be
required to antagonize senescence during tumorigenesis.
p21
Cip1 is a key player during the induction of senescence of
human fibroblasts [39], keratinocytes [40], melanocytes [41] and
mammary epithelial cells [42]. While we did not detect senescent
cells in tumors that arose in either wild type or Miz1DPOZ
occur in the skin of Miz1DPOZ mice (D, H). Immunohistochemistry for the proliferation marker Ki67 revealed positive cells in the basal cell layer of
untreated skin in both genotypes (I, K) and the labelling index was not significantly different (M, 2TPA; n=5 for each genotype). After TPA treatment,
the Ki67 labelling index in Ctr animals was about twice as high as in Miz1DPOZ animals (M, +TPA; n=5 for each genotype; Ctr vs Miz1DPOZ for 6 TPA:
p,0.0001). In addition, Ki67 positive cells were scattered through the suprabasal cell layers of the epidermis in Ctr but not in Miz1DPOZ animals (J, L).
Bar: 50 mm.
doi:10.1371/journal.pone.0034885.g002
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and approximately 25% of the hair follicles stain positive for the
senescence marker SA-ß-galactosidase in aged skin of Miz1DPOZ
but not of control animals (Figure S9; [43]). We suggest, therefore,
that repression via Miz1 may be more broadly involved in
suppressing senescence and the reduced tumorigenesis in Miz1D-
POZ mice may reflect the need to overcome p21
Cip1 mediated
senescence during tumor formation [44,45]. While this remains to
be formally demonstrated, the current data strongly support the
view that the formation of a functional Miz1/Myc complex results
in a context-dependent and cell type-specific attenuation, or even
abrogation, of critical growth arrest pathways during tumorigen-
esis.
Materials and Methods
Transgenic mice
Miz1
lox/lox mice [20] were crossed with K14Cre mice [19] to
generate a conditional knockout of the POZ domain of Miz1 in
murine basal epidermal cells as described elsewhere [20]. Mice
were backcrossed 6 times on a 129S2/SvHsd background. Here,
mice which are K14cre
+;Miz1
flox/flox are designated MizDPOZ-
mice, while K14Cre
2;Miz1
flox/flox mice were used as control
animals designated Ctr. MizDPOZ mice were crossed on a cdkn2b
[46] and cdkn1a [47] deficient background, here designated
MizDPOZ;cdkn2b
2/2 and MizDPOZ;cdkn1a
2/2 mice, respectively.
cdkn2b
2/2 animals, with a FVB background, were a generous gift
from A. Burns, Amsterdam. cdkn1a
2/2 animals, with a 129S4/
SvJae genetic background, were purchased from Jackson labora-
tory (stock no. 008184).
49 d old mice were treated on 5 consecutive days with 5 nmol
TPA (Sigma) in 100 ml acetone. TPA was locally applied on the
dorsal skin, which was shaved 1 week before the first treatment.
The mice were sacrificed 24 h after the last treatment.
In the 2-stage tumorigenesis experiment [29], 100 nmol DMBA
(Sigma) in 100 ml acetone was once applied on the shaved dorsal
skin of 49 d old mice. 1 week after the DMBA-application, the
TPA treatment was started. Mice were then treated with 5 nmol
TPA in 100 ml acetone for 20 weeks with two TPA applications
per week.
Label-retaining cells (LCRs) were demonstrated in a bromode-
soxyuridine (BrdU) pulse-chase experiment. On day 10 post
partum (P10), 10 mg BrdU dissolved in 50 ml sterile PBS were
injected intraperitoneally 5 times once every hour. On days P18 to
P23 animals were treated with TPA as described above and the
skin was prepared for histology. Immunocytochemical staining of
BrdU was performed as described below.
Research involving mice have been conducted according to the
German Animal Protection Law (Tierschutzgesetz). The applica-
tion for the experiments was reviewed and approved by the
responsible local authorities (Regierungspraesidium Giessen,
reference numbers V 54 - 19 c 20/15 (1) MR20/10 Nr. 23/
2005, V 54 - 19 c 20/15 (1) MR20/10 Nr. 95/2009 and V 54 - 19
c 20/15 (1) MR20/10 Nr. 66/2010)
Immunoblot analysis
Protein samples were extracted from dorsal skin and homog-
enized in RIPA buffer, containing 1% Triton X-100; 1% sodium
deoxycholate; 0,1% SDS; 150 mM NaCl; 10 mM Na2HPO4;
2 mM EDTA; 1% Apronitin; 50 mM NaF; 200 mM Na3VO4;
pH 7,4. As a positive control for p21
cip1, extracts from sciatic
nerves were used [48]. Protein concentration was determined
using the BCA-assay (Sigma). 20 mg per sample were separated on
10% polyacrylamide-SDS gels according to standard procedures.
Proteins were blotted on nitrocellulose membranes and the blots
were stained with antibodies against the following proteins: c-Myc
(N-262, Santa Cruz; 1:400), p21 (C-19, Santa Cruz; 1:100), p-
ERK (T202/Y204, Cell Signalling; 1:200), p53 (FL-393, Santa
Cruz; 1:400), tubulin (YL1/2, Abcam; 1:2000) at 4uC overnight or
for 72 hours in case of p53. Appropriate secondary peroxidase
labelled antibodies (Biorad) were applied 1 hour at room
temperature and antibody binding was visualized using the
Lumi-Light Western blotting substrate from Roche.
Chromatin immunoprecipitation assay
Chromatin immunoprecipitation was carried out according to
Boyd [49] using the mouse keratinocyte cell line PAM212 [27].
Briefly, the chromatin was sonicated at 4uC using a Bioruptor
TM
NextGen (Diagenode) for 15630 sec at 20 Hz and 320 W with
30 sec breaks between each sonication step. The Immunoprecip-
itation Starter Pack (GE Healthcare) was used with antibodies
directed against c-Myc (N-262; Santa Cruz)andMiz1(10E2,Staller
et al. 2001). For the isotype control, IgG from mouse and rabbit
serum (Sigma) was used.Afterthecrosslinkreversion, the chromatin
was purified with the QIAquick PCR Purification Kit (QIAGEN).
The promoter binding was detected by qPCR on a Mx3005p
PCR machine (Stratagene/Agilent) with a QPCR SYBR Green
Mix (Thermo Scientific), using CTCAGCTCTAACTG-
TACTGTTGTTCA as forward and CTGGGCTATTCTC-
TTGTCACG as reverse primer, to detect the cdkn1a promoter
sequence by amplifying genomic DNA between basepairs
29.230.454–29.230.529 of chromosome 17. Control primers were
TCATCCCACCCAGGAGTATT as forward primer and GAG-
TACATTTAACCAACTATCAGAGCA as reverse primer, re-
spectively, amplifying genomic DNA between basepairs
9.600.536–9.600.628 of chromosome 17 being unrelated to cdkn1a.
Histology
Skin samples were fixed in PBS buffered 3.7% formaldehyde
and embedded in paraffin according to standard procedures. For
immunohistochemistry, 3 mm sections were applied on silane-
coated slides, preincubated with 10% goat serum (Sigma) and, if
Figure 3. Altered proliferation in the skin of Miz1DPOZ mice depends on p21
Cip1. TPA treatment of skin from control (Ctr) and Miz1DPOZ
mice on a cdkn1a null background shows the same increase of the Ki67 labelling index and scattering of Ki67 positive cells in the suprabasal layers of
the epidermis (A–D and F; n=3 for each genotype and condition; Ctr vs Miz1DPOZ for 2TPA: p=0.4007; Ctr vs Miz1DPOZ for +TPA: p=0.4494). In
contrast, the equivalent experiment on a cdkn2b null background (E; n=3 for each genotype and condition) exhibited the same result as in cdkn2b
+/+
animals (compare with Figure 2 M; Ctr vs Miz1DPOZ for 6TPA: p,0.0001). In cdkn1a
+/+ animals, p21
Cip1 is upregulated in protein extracts from
Miz1DPOZ-mice (DPOZ) compared to extracts from control-mice (Ctr) either with or without TPA-treatment (I). Sciatic nerve extracts from cdkn1a
+/+
and cdkn1a
2/2 animals were used as positive and negative controls, respectively (see Materials and Methods). Chromatin immunoprecipitation assay
using chromatin from murine PAM212 keratinocytes and antibodies against Miz1 and Myc (G; H; one representative experiment of three
independent experiments each). The experiment demonstrates that both transcription factors bind to the cdkn1a promoter in this cell type. Miz1
binds to the cdkn1a promoter in PAM212 keratinocytes, without and with TPA treatment (100 nM for 4 hours). Primers used either amplified genomic
DNA comprising part of the cdkn1a promoter (p21) or a cdkna1a unrelated sequence of chromosome 17 (ctr). For details see Materials and Methods.
The graphs show the mean value of 2–3 technical replicas.
doi:10.1371/journal.pone.0034885.g003
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Cip1
and p-ERK staining, slides were microwaved in 10 mM citrate
buffer pH 6 for 365 min. For bromodesoxyuridine (BrdU)
staining, slides were incubated for 30 min in 2 N HCl/0.5%
Triton X-100, for 3 min in borax buffer (0.5 M sodium diborate/
0,5 M boric acid, pH=7.6) at RT and for 3 min in 0.025%
trypsin in 0,05 M Tris/HCL, pH=7.4. Primary antibodies were
diluted in 10% goat serum (Dako) and incubated at 4uC overnight.
Antibodies against the following antigens were used: Ki67 (Dako;
1:50), BrdU (Dianova; 1:100), p-ERK (T202/Y204, Cell Signal-
ling; 1:100), CD34 (BD; 1:100), K15 (Abcam; 1:100), p21
Cip1
(Abcam; 1:100), keratin 1 (Covance, 1:1000), loricrin (Covance;
1:1000). For visualization, appropriate secondary antibodies
labelled either with FITC, TRITC (Molecular Probes) or with
peroxidase were used. Slides were incubated 1 hour at room
temperature and were subsequently covered with Mowiol. For
documentation, a motorized BX61 microscope (Olympus)
equipped with a F-View digital camera was used (Soft Imaging
System, Mu ¨nster, Germany).
The TUNEL assay was performed using the DeadEnd kit
(Promega) according to manufacturer instructions. The staining
for SA-ß-galactosidase was performed as described by Dimri et al.
[43]. To ascertain the percentage of positive hair follicles, about
100 follicles per sample were counted.
Morphometric analysis
The number of Ki67 positive cells per mm of skin and the ratio
of suprabasal Ki67 positive cells were measured using the program
cell
F (Olympus). From 3 to 5 mice per condition (control,
MizDPOZ, MizDPOZ;cdkn2b
2/2 and MizDPOZ;cdkn1a
2/2; TPA-
treated and untreated) 15–25 pictures were taken. In each picture,
the length of the epidermis was measured and the related Ki67
positive basal and suprabasal cells were counted. The amount of
all Ki67 positive cells per mm of skin was calculated. In addition,
the ratio of basal to superbasal Ki67 positive cells was determined.
Statistical analysis
Mean values and standard deviations of the morphometric and
ChIP data were calculated with Excel (Microsoft). The statistical
significance of the morphometric data, the Kaplan-Meier
estimator and the average number of tumors per mouse was
calculated using the Student’s t-test as implemented in the
program GraphPad Prism (GraphPad Software).
Supporting Information
Figure S1 Label-retaining cells (LRCs) in the bulge
region. (A) Documentation of LRC number variability in bulge
regions from ctr and Miz1DPOZ animals, without and with TPA
treatment. In (B), the percentage of LRCs (% BrdU positive cells)
counted in the bulge region area are shown. 19 to 25 bulge regions
per condition were evaluated for BrdU positive cells.
(TIF)
Figure S2 TPA treated control and Miz1DPOZ epider-
mis. HE-staining of control (A, B) and Miz1DPOZ epidermis (C,
D) under TPA treatment (B, D) or in untreated skin (A, C). The
size of scale bar in A is 50 mm. The average epidermal thickness of
TPA treated and untreated control and Miz1DPOZ epidermis is
shown in E. 100 single measurements per animal were done with 3
animals per condition. Fluorescence staining of filaggrin in control
(F, G) and Miz1DPOZ (H, I) skin with and without TPA treatment
(+/2TPA). Filaggrin is equally expressed in Ctr and Miz1DPOZ
suprabasal epidermis, either with or without TPA treatment.
Percentage of suprabasal Ki67 positive keratinocytes in untreated
and TPA treated Ctr and Miz1DPOZ skin (J).
(TIF)
Figure S3 TPA treated control and Miz1DPOZ epider-
mis with a cdkn2b
2/2 background. Fluorescence staining of
Ki67 in Ctr (A, B) and Miz1DPOZ (C, D) skin with a cdkn2b
(encoding p15
INK4b) deficient background with and without TPA
treatment (+/2TPA). The additional deletion of cdkn2b does not
rescue the reduced proliferation in TPA treated Miz1DPOZ skin
compared to TPA treated Ctr skin. Quantification of suprabasal
Ki67 positive keratinocytes in untreated and TPA treated Ctr and
Miz1DPOZ skin with either a p15
INK4b (E) or a p21
cip1 (F) deficient
background. Under TPA treatment, suprabasal Ki67 positive cells
are significantly reduced in Miz1DPOZ skin compared to Ctr skin
in mice with a cdkn2b
2/2 background (E; p,0.0001), as observed
in cdkna2b
+/+ animals (compare with Figure S2 J). In contrast, a
complete rescue was achieved in cdkn1a
2/2 animals where no
difference of Ki67 suprabasal cells was observed between control
and Miz1DPOZ mice (F; p=0.9316).
(TIF)
Figure S4 Differentiation in cdkn2b or cdkn1a deficient
Miz1DPOZ epidermis. Fluorescence staining of keratin 1 (A–
H) and loricrin (I–P) in control and Miz1DPOZ skin with and
without TPA treatment (+/2TPA) either with a cdkn2b (A–D and
I–L) or cdkn1a (E–H and M–P) deficient background. In cdkn2b
2/2
mice and upon TPA treatment, keratin 1 expression is focally
interrupted in Ctr skin while Miz1DPOZ skin shows continuous
keratin 1 expression (B, D). With a cdkn1a deficient background,
Ctr and Miz1DPOZ skin both show a focal interruption of keratin 1
expression after TPA (F, H). Also, with a cdkn2b
2/2 background,
loricrin expression is focally reduced in Ctr skin (J) but not in
Miz1DPOZ skin (L), while in cdkn1a
2/2 skin, focal reduction of
loricrin expression can be observed in both Ctr (N) and Miz1DPOZ
skin (P). The described expression patterns of keratin 1 and loricrin
only occurred in TPA treated skin, whereas untreated skin did not
show differences between Ctr and Miz1DPOZ animals in regard to
keratin 1 and loricrin expression, neither with a cdkn2b (A, C, I, K),
nor with a cdkn1a deficient background (E, G, M, O).
(TIF)
Figure S5 ERK-phosphorylation, c-Myc and p53 expres-
sion in Miz1DPOZ epidermis. Immunoblot of phosphorylated
Figure 4. Formation of skin papillomas is decreased in Miz1DPOZ mice. (A) Animals with a conditional knockout of the Miz1DPOZ domain in
keratinocytes (n=26) showed a reduced development of skin papillomas relative to control (Ctr) mice (n=23; p,0.001). In addition, the average
number of tumors per mouse was significantly reduced in Miz1DPOZ animals compared to control animals (B). With a cdkn1a null background, tumor
development (C) and average number of tumors per animal (D) in Ctr (n=22) and Miz1DPOZ (n=26) mice were not significantly different (tumor
development: p=0.9789; tumors per animal: p=0.1585). In (E), representative tumors of all genotypes are shown documenting a smaller size of
tumors in Miz1DPOZ mice with a cdkn1a
+/+ background. This is confirmed by the quantification of the tumor diameters (H; Ctr vs. Miz1DPOZ:
p,0.0001). In contrast, tumor size on a cdkn1a
2/2 background was not significantly different between control and Miz1DPOZ animals (I; Ctr vs.
Miz1DPOZ: p=0.8788). When tumor tissue with a cdkn1a
+/+ background was stained with an antibody against p21
Cip1, 14 out of 15 tumors from 9
Miz1DPOZ mice exhibited a strong staining (G), while p21
Cip1 expression was not detectable in 19 out of 21 tumors from 7 wild type mice (F) (see also
Figure S8).
doi:10.1371/journal.pone.0034885.g004
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and Miz1DPOZ skin (A), untreated or treated with TPA (2/
+TPA). a-tubulin was used as a loading control. The expression of
p-ERK was also visualized in murine epidermis via immunohis-
tochemistry in control (B, C) and Miz1DPOZ samples (D, E) both
untreated (B, D) or TPA treated (C, E). Furthermore, p53 stained
by immunohistochemistry in tumors did not reveal a difference
between control (Ctr) and Miz1DPOZ papillomas (F, G), in contrast
to p21
cip1 expression (see Figure 4F, G and Figure S8).
(TIF)
Figure S6 Histology and genotyping of Miz1DPOZ
papillomas. HE-staining of control (A, C, D, G) and Miz1DPOZ
papillomas (B, E, F, H). The length of the scale bars is 600 mmi n
A and B, 100 mm in C–F and 50 mm in G and H. (I) Miz1
genotyping of murine tail skin (S) and tumor tissue (T). A control
(Ctr) animal and one tumor with a floxed Miz1 allele and no Cre
recombinase expression was genotyped as a negative control.
Animals 1–11 are Miz1DPOZ animals with a floxed Miz1 allele
which express Cre recombinase. The lower band at 180 bp
indicates the recombinant allele, while the upper band at 311 bp
indicates the floxed allele. A floxed allele can also be detected in
tumors from Miz1DPOZ animals due to the presence in the
samples of other (non-keratinocyte) epidermal and dermal cell
types that do not express Cre recombinase.
(TIF)
Figure S7 Apoptosis and tumor growth in tissue from
control (ctr) and Miz1DPOZ animals. (A) While there were
essentially no TUNEL positive cells in the interfollicular skin, we
occasionally observed TUNEL positive cells in tumors indepen-
dent of the genotype, although most tumors from both genotypes
lacked TUNEL positive cells. As a positive control for the assay we
used either skin fixed in Carnoy’s solution, where most nuclei
should be positive because of an acidic hydrolysis of the DNA (due
to the acetic acid which is a component of this fixative) or thymus
which usually exhibits a large number of apoptotic T-cells,
predominately in the cortex. (B) Tumor development during 17
weeks after the last TPA treatment. Representative pictures of
control (Ctr) and Miz1DPOZ papillomas 17 weeks after the last
TPA treatment (B). Measurement of the tumor diameter (C)
revealed an increased tumor-size in Ctr animals but not in
Miz1DPOZ mice (compare with Figure 4H).
(TIF)
Figure S8 p21-expression in Miz1DPOZ papillomas.
Immunohistochemistry of control (Ctr) and Miz1DPOZ papillomas
showing the expression of p21
cip1 (A). Each slide indicates a
representative region of an individual tumor. In the majority of
Miz1DPOZ papillomas, p21
cip1 was upregulated, whereas in most
Ctr tumors p21
cip1 expression was not detectable. Expression of
p21 protein in papillomas was also analyzed by immunoblot (B) in
each of three (1–3) Ctr and Miz1DPOZ papillomas with p21
+/+. Ctr
and Miz1DPOZ tumor samples with a p21
2/2 background are
negative controls. All Miz1DPOZ-tumors have an increased p21
expression compared to Ctr tumors, while in p21
2/2 tumors, no
p21 expression was detectable.
(TIF)
Figure S9 Tumors of Miz1DPOZ mice are not positive
for SA-ß-galactosidase. Tumors from control (Ctr) (A) and
Miz1DPOZ (B) animals after 20 weeks of TPA treatment were
histochemically stained for SA-ß-galactosidase, but were not
positive independent of the genotype. In contrast, skin from one
year old Miz1DPOZ mice displayed a focal staining which was
absent in Ctr animals (C, D). In addition, about 25% of hair
follicles stained positive for SA-ß-galactosidase in Miz1DPOZ but
not in Ctr animals (E). Arrowheads indicate sebaceous glands,
which stain always positive for SA-ß-galactosidase.
(TIF)
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